Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Jim Cramer Says You Should Buy This ‘Strong Buy’ Stock ‘Hand Over Fist’

Cramer explains why this pharmaceutical company is a buy as it outperforms a key rival.

Ozempic-maker Novo Nordisk Says CEO To Step Down

Ozempic-maker Novo Nordisk Says CEO To Step Down

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake of "market challenges".

International Business Times

Novo Nordisk CEO steps down amid growing competition for weight loss drugs

Novo Nordisk CEO steps down amid growing competition for weight loss drugs

Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

This Pharma Stock Is Still a ‘Strong Buy’ Despite Trump’s Plans to Lower Drug Prices

Despite Trump’s executive order to cut drug prices, Eli Lilly’s stock surged, showing strong resilience and impressive gains amidst regulatory concerns.

Are Wall Street Analysts Bullish on Eli Lilly Stock?

Despite lagging behind the broader market over the past year, Eli Lilly continues to enjoy a highly bullish outlook from Wall Street analysts, who remain confident in the company’s long-term growth potential.

Wegovy maker Novo Nordisk cuts profit forecast as US prescriptions tail off

Slowdown will deepen concerns Denmark’s biggest company is losing market share to US rival Eli Lilly

The Guardian - UK

Novo Nordisk cuts guidance as weight-loss drug market competition grows

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug markets.

inkl

Read news from The Economist, FT, and more,
with one subscription

Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant?

This Left-for-Dead Penny Stock Just Got a Major Boost. Should You Buy It Now?

This Left-for-Dead Penny Stock Just Got a Major Boost. Should You Buy It Now?

This penny stock has received a big boost after reports of bankruptcy began to circulate.

World Health Organization makes U-turn on weight loss jabs

World Health Organization makes U-turn on weight loss jabs

The decision is a significant shift in the WHO’s approach to drugs like Wegovy

The Independent UK

Trump hints at tariff reprieve for pharma companies that bring operations back to US

Trump hints at tariff reprieve for pharma companies that bring operations back to US

He suggests drugmakers would get ‘a lot of time’ to repatriate manufacturing before facing levies

The Guardian - UK

Stocks Soar Before the Open on Upbeat Microsoft and Meta Results, More Big Tech Earnings on Tap

Stocks Soar Before the Open on Upbeat Microsoft and Meta Results, More Big Tech Earnings on Tap

June S&P 500 E-Mini futures (ESM25) are up +1.18%, and June Nasdaq 100 E-Mini futures (NQM25) are up +1.68% this morning as forecast-beating quarterly results from Microsoft and Meta boosted sentiment.

Viagra and Mounjaro panic-buying could explain Ireland's 200% export surge to U.S.

Viagra and Mounjaro panic-buying could explain Ireland's 200% export surge to U.S.

U.S. multinational activity propelled the Irish economy to 3.2% growth in the first quarter, as Trump fears come into focus.

Ozempic maker spending more than $3m to lobby fat cats in Washington as weight-loss drugs faces regulatory decisions

Ozempic maker spending more than $3m to lobby fat cats in Washington as weight-loss drugs faces regulatory decisions

Novo Nordisk has hired multiple lobbying firms to persuade lawmakers to take a harder line on companies producing versions of the drugs that have not been approved by the FDA

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

2 ‘Strong Buy’ Stocks to Buy on Plans to Increase American Manufacturing

Two checkered names from diverse industries are looking to bolster their manufacturing capabilities in the U.S. Here's how they stack up as investment ideas.

Trade war with China to hit US healthcare

Without a carve-out for tariff exceptions for pharmaceuticals, prices will skyrocket for US patients, experts warn.

Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY

Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring. The company has a big opportunity to serve needle-phobic patients.

Eli Lilly's Quarterly Earnings Preview: What You Need to Know

Eli Lilly is scheduled to report its first-quarter results next month, and analysts expect a significant double-digit earnings growth.

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Swiss drugmaker Roche to invest $50bn in US in effort to dodge Trump tariffs

Company says it will create 12,000 jobs in manufacturing and R&D over next five years

Goldman Sachs Just Upgraded This Blue-Chip Stock. Should You Buy It Now?

With a strong pipeline, this pharmaceutical powerhouse is positioning itself as a dominant force in the future of medicine.

The Independent UK

Daily weight-loss pill may work as well as Ozempic and could replace injections

Patients in a trial taking orforglipron lost an average of 7.2kg over nine months

The Guardian - UK

New daily weight-loss pill shows success at clinical trial

Orforglipron also reduced blood sugar levels in participants with type 2 diabetes

Experimental daily pill found to aid weight loss in what could be alternative to jabs like Ozempic

Other weight loss drugs must be injected, meaning the new pill from pharmaceutical giant Eli Lilly could become patients’ top choice if it is approved.

Analysts Love These 2 Stocks to Buy for Q2

Investors could snag these two stocks as BofA flags the companies as well-positioned winners in an uncertain quarter.

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

1 … 14 15 16 17

People

200,285 stories

Robert F. Kennedy Jr

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

the White House

Amazon.com Inc.

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Executive Order

Places

393,871 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play